The estimated Net Worth of Lawrence Martin Weiss is at least $3.32 Millón dollars as of 22 April 2021. Lawrence Weiss owns over 25,050 units of Neogenomics stock worth over $2,134,115 and over the last 6 years he sold NEO stock worth over $0. In addition, he makes $1,183,670 as Chief Medical Officer at Neogenomics.
Lawrence has made over 2 trades of the Neogenomics stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 25,050 units of NEO stock worth $503,756 on 22 April 2021.
The largest trade he's ever made was exercising 109,004 units of Neogenomics stock on 14 December 2020 worth over $1,024,638. On average, Lawrence trades about 22,342 units every 21 days since 2018. As of 22 April 2021 he still owns at least 130,847 units of Neogenomics stock.
You can see the complete history of Lawrence Weiss stock trades at the bottom of the page.
Dr. Lawrence Martine Weiss M.D. serves as Chief Medical Officer of the Company. Dr. Weiss has served the Company as Chief Scientific Officer since December 2018. Prior to this, he has served as Medical Director and Director of Pathology Services since December 2015. Prior to joining the Company, Dr. Weiss served at Clarient Diagnostic Services, Inc. as a Pathologist and subsequently as Laboratory Director from 2011 through 2016. Dr. Weiss is currently a Visiting Professor in the Department of Pathology and Medicine for the University of California at Irvine. Dr. Weiss received his B.S. and M.D. summa cum laude from the University of Maryland.
As the Chief Medical Officer of Neogenomics, the total compensation of Lawrence Weiss at Neogenomics is $1,183,670. There are 2 executives at Neogenomics getting paid more, with Douglas VanOort having the highest compensation of $3,648,730.
Lawrence Weiss is 63, he's been the Chief Medical Officer of Neogenomics since 2019. There are 4 older and 21 younger executives at Neogenomics. The oldest executive at Neogenomics Inc. is Raymond Hipp, 77, who is the Independent Director.
Lawrence's mailing address filed with the SEC is 12701 COMMONWEALTH DRIVE SUITE 9, , FORT MYERS, FL, 33913.
Over the last 12 years, insiders at Neogenomics have traded over $310,374,253 worth of Neogenomics stock and bought 167,456 units worth $1,699,153 . The most active insiders traders include Electric Coge Medical Syste..., Oort Douglas M Van y Steven C Jones. On average, Neogenomics executives and independent directors trade stock every 23 days with the average trade being worth of $2,654,175. The most recent stock trade was executed by Alicia C Olivo on 15 August 2024, trading 1,040 units of NEO stock currently worth $16,692.
neogenomics laboratories is a leading cancer diagnostic reference laboratory that has provided high-quality cancer testing and partnership programs to pathologists and oncologists for over 10 years. we work every day to achieve our common purpose of saving lives by improving patient care through communication, accuracy, reliability, and efficiency. our areas of expertise include cancer cytogenetics with industry-leading turnaround times; hematologic and solid tumor fish testing with the largest menu of technical-only services available; 10-color flow cytometry; ihc supported by an extensive antibody library; and over 100 molecular oncology tests comprising the most comprehensive combination of multiparameter profiles and targeted biomarker tests in the industry. our technical-only testing programs feature on-demand or live training and are available to pathologists who wish to sign out fish, flow cytometry, and/or ihc. neogenomics’ extremely fast test development cycle means we are hig
Neogenomics executives and other stock owners filed with the SEC include: